The European Medicines Agency (EMA) assured the public on Thursday that there is no evidence that the AstraZeneca vaccine is directly related to cases of thromboembolism found after vaccination in different European countries. Therefore, it believes that the continued use of the drug in sports is Safe immunity against covid-19.
At a press conference in Brussels on Thursday, the Executive Director of the European Medicines Agency (EMA) Emer CookeAccording to EFE, AstraZeneca’s vaccine is a conclusion drawn from the analysis of its experts during the two-week research process: AstraZeneca’s vaccine is “safe and effective” and “benefits and protects” citizens of covid-19 .
The person in charge of EMA added that the administration of the drug “has nothing to do with the increase in thrombosis,” but emphasized that she cannot completely rule out the relationship with thrombosis. Rare cases of thromboembolism, So it will continue to investigate.
“The vaccine may be associated with a very rare blood clot, ThrombocytopeniaThe agency added that with or without bleeding, the level of platelets in the blood is low (an element in the blood that helps blood clot).
Cooke added that in the population using this vaccine, “there is no general risk” that will lead to the development of blood clotting problems, and that through this survey, EMA has fulfilled its “responsibility to determine that the benefits still outweigh the benefits.” The “risk” of authorized drugs.
EMA has not yet seen “evidence of problems related to specific batches of vaccines or specific production locations” from AstraZeneca.
Similarly, the European Health Commissioner Stella Kyriakides, Announced through his Twitter account: “The EMA Pharmacovigilance Committee has reached a clear scientific conclusion: AstraZeneca’s #COVID19 vaccine is safe and effective, and its benefits outweigh all risks.” However, he pointed out that “with vaccination Very close monitoring will be essential for the continued progress of the country. Safety remains the top priority.”
Security and trust
In this sense, the commissioner emphasized that “vaccine safety and confidence are essential for vaccination.” Therefore, he emphasized that the top priority of the European Commission “has always been the safety of any covid-19 vaccine approved for use in the EU. And effectiveness.”
To this end, he added that Brussels ensures that “all vaccines are subject to strict and independent safety inspections by the European Medicines Agency before vaccination.” He emphasized: “This has always been non-negotiable for us.”
The EU’s conditional marketing authorization “also requires Pharmacovigilance system Ensure that any possible drug-related problems, no matter how rare, will not attract people’s attention.
After nearly two weeks of investigation, its Safety Committee (PRAC) failed to find scientific evidence linking the thromboembolism cases reported in certain European countries to the AstraZeneca vaccine. Some countries have suspended the study for precautions. . People who receive thrombosis have seizures.
For its part, AstraZeneca said on Thursday that it will implement the EMA’s recommendations for a vaccine against covid-19, including updates Product information on the package insert Warn of possible risks.